Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 5:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Skin Cancer Face Clear all
Completed Phase 2 Interventional

Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (isSCC)

NCT06159842
View directory record Official record
Conditions
Facial Cutaneous Squamous Cell Carcinoma in Situ
Interventions
Aminolevulinic Acid 20% Topical Solution with Blue Light
Combination Product
Lead sponsor
The Center for Clinical and Cosmetic Research
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Sep 20, 2026, 5:09 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of Ingenol Mebutate Once Daily for 2 or 3 Consecutive Days in Subjects With Actinic Keratosis

NCT01820260
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Ingenol mebutate gel, placebo
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Carmel, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Sep 20, 2026, 5:09 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Tranexamic Acid in Nasal Mohs Reconstruction

NCT06057675
View directory record Official record
Conditions
Postoperative Bleeding, Skin Cancer Face
Interventions
Treatment (tranexamic acid and 1% lidocaine with 1:100,000 epinephrine), Control (1% lidocaine with 1:100,000 epinephrine)
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 20, 2026, 5:09 AM EDT
Not yet recruiting Phase 3 Interventional Accepts healthy volunteers

Basal Cell Carcinoma Chemoprevention Trial

NCT05212246
View directory record Official record
Conditions
Basal Cell Carcinoma
Interventions
5% Imiquimod cream, Placebo Vehicle Control Cream
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
1,630 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2032
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 20, 2026, 5:09 AM EDT
Not listed Phase 2 Interventional

Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (SCCis)

NCT06577311
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma
Interventions
Aminolevulinic acid hydrochloride 10% topical gel with Red Light
Combination Product
Lead sponsor
The Center for Clinical and Cosmetic Research
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Sep 20, 2026, 5:09 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Topical Antibiotic Prophylaxis for Eyelids

NCT03199911
View directory record Official record
Conditions
Antibiotic Side Effect, Eyelid; Wound, Eyelid Diseases, Surgical Wound Infection, Surgical Wound, Recent, Surgical Incision, Skin Cancer Face, Antibiotic Allergy, Surgical Site Infection
Interventions
Topical Antibiotic Product, Topical Non-Antibiotic Ointment
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
401 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Sep 20, 2026, 5:09 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study to Evaluate Two Concentrations of DFD-07 Cream, in Subjects With Actinic Keratosis (AK) of the Face and/or Scalp Over a 12-week Treatment Period

NCT03116698
View directory record Official record
Conditions
Actinic Keratosis (AK)
Interventions
Low dose DFD07 once daily, High dose DFD07 once daily, High dose DFD07 twice daily, Placebo twice daily
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
20
States / cities
Cerritos, California • Fremont, California • Palm Springs, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Sep 20, 2026, 5:09 AM EDT
Withdrawn No phase listed Observational

Facial Skin Health Tracking Feasibility in Breast Cancer Patients

NCT04035408
View directory record Official record
Conditions
Breast Cancer Female
Interventions
Skin health assessment
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 4, 2023 · Synced Sep 20, 2026, 5:09 AM EDT
Completed Not applicable Interventional

A Bioequivalence Study With Clinical Endpoints Comparing Generic Imiquimod Cream, 3.75% and Zyclara™ (Imiquimod) Cream, 3.75% in Subjects With Actinic Keratoses

NCT01502020
View directory record Official record
Conditions
Actinic Keratoses
Interventions
imiquimod cream, 3.75%, Vehicle Cream
Drug
Lead sponsor
Actavis Mid-Atlantic LLC
Industry
Eligibility
18 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
19
States / cities
Birmingham, Alabama • Miami, Florida • Newnan, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2011 · Synced Sep 20, 2026, 5:09 AM EDT
Completed Phase 1 Interventional

Treatment of Actinic Keratoses (AK) on the Face

NCT02411851
View directory record Official record
Conditions
Actinic Keratoses
Interventions
ingenol mebutate 0.015%, dermasil lotion
Drug · Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Sep 20, 2026, 5:09 AM EDT
Completed Phase 3 Interventional Results available

An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome

NCT00936741
View directory record Official record
Conditions
Cushing's Syndrome
Interventions
mifepristone
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
15
States / cities
Birmingham, Alabama • Escondido, California • Stanford, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2014 · Synced Sep 20, 2026, 5:09 AM EDT
Completed Phase 4 Interventional Results available

Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses

NCT00774787
View directory record Official record
Conditions
Actinic Keratoses
Interventions
imiquimod 5% cream
Drug
Lead sponsor
Rigel Dermatology
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
3
States / cities
St. Petersburg, Florida • Henderson, Nevada • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 6, 2016 · Synced Sep 20, 2026, 5:09 AM EDT
Terminated Phase 2 Interventional Results available

Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex

NCT03363763
View directory record Official record
Conditions
Angiofibroma of Face, Tuberous Sclerosis
Interventions
Sirolimus 0.2%, Sirolimus 0.4%, Placebo ointment
Drug
Lead sponsor
Aucta Pharmaceuticals, Inc
Industry
Eligibility
2 Years to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
7
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2025 · Synced Sep 20, 2026, 5:09 AM EDT
Terminated Phase 4 Interventional Results available

Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy

NCT01203878
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Photodynamic therapy, Imiquimod
Drug
Lead sponsor
Tennessee Clinical Research Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
Englewood, Colorado • Charlotte, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 7, 2014 · Synced Sep 20, 2026, 5:09 AM EDT
Withdrawn Phase 3 Interventional

Phase 3 Study of Levulan With New Blue Light for AK on the Face or Scalp

NCT03024060
View directory record Official record
Conditions
Actinic Keratosis
Interventions
ALA, Vehicle, IBL 20 mW, IBL 10 mW
Drug · Device
Lead sponsor
DUSA Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
7
States / cities
San Diego, California • Arlington Heights, Illinois • Carmel, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Sep 20, 2026, 5:09 AM EDT
Completed Phase 2 Interventional Results available

Activity & Safety Study of KX2-391 Ointment in Participants With Actinic Keratosis on the Face or Scalp

NCT02838628
View directory record Official record
Conditions
Actinic Keratosis
Interventions
50 mg of KX2-391 Ointment 1%
Drug
Lead sponsor
Almirall, S.A.
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
16
States / cities
Fremont, California • La Mesa, California • Palm Springs, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Sep 20, 2026, 5:09 AM EDT
Completed Phase 3 Interventional

Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp

NCT00306800
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Photodynamic therapy with methyl aminolevulinate cream
Procedure
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
7
States / cities
St. Petersburg, Florida • New York, New York • Rochester, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 20, 2026, 5:09 AM EDT
Completed Phase 3 Interventional Results available

Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis

NCT01686152
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Imiquimod Cream, 3.75%, Zyclara®, Vehicle of Test Product
Drug · Other
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
589 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
23
States / cities
Tucson, Arizona • Encino, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Sep 20, 2026, 5:09 AM EDT
Completed Phase 1 Interventional

Tuberous Sclerosis Complex: Facial Angiofibroma Skin Cream

NCT01853423
View directory record Official record
Conditions
Facial Angiofibroma
Interventions
Rapamune
Drug
Lead sponsor
Le Bonheur Children's Hospital
Other
Eligibility
3 Years to 45 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 18, 2016 · Synced Sep 20, 2026, 5:09 AM EDT
Completed Phase 3 Interventional Results available

A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on Actinic Keratosis on Face or Scalp (AK004)

NCT03285490
View directory record Official record
Conditions
Actinic Keratosis
Interventions
KX2-391 Ointment 1%, Placebo
Drug
Lead sponsor
Almirall, S.A.
Industry
Eligibility
18 Years and older
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
30
States / cities
Phoenix, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Sep 20, 2026, 5:09 AM EDT
Completed Phase 4 Interventional

Bilateral Comparison of Treatment of Facial Actinic Keratoses Using Microneedling and Photodynamic Therapy With Aminolevulinic Acid and Blue Light Versus Photodynamic Therapy With Aminolevulinic Acid and Blue Light Using Two Incubation Times

NCT02622594
View directory record Official record
Conditions
Actinic Keratoses
Interventions
Aminolevulinic Acid (ALA), Environ Cosmetic Roller, BLU-U IIlluminator
Drug · Device
Lead sponsor
Dermatology, Laser & Vein Specialists of the Carolinas
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Sep 20, 2026, 5:09 AM EDT
Completed Phase 1 Interventional

Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors

NCT00413322
View directory record Official record
Conditions
Tumor
Interventions
belinostat, 5-Fluorouracil (5-FU)
Drug
Lead sponsor
Valerio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
Scottsdale, Arizona • Omaha, Nebraska • Portsmouth, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 7, 2015 · Synced Sep 20, 2026, 5:09 AM EDT
Completed Phase 2 Interventional Results available

Short-incubation Levulan Photodynamic Therapy Versus Vehicle for Face/Scalp Actinic Keratosis (AK)

NCT01475955
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Broad Area ALA 1-hour incubation, Broad Area ALA 2 hour incubation, broad area ALA 3-hour incubation, Spot ALA 2 hour incubation, Vehicle PDT, Blue Light Treatment
Drug · Device
Lead sponsor
DUSA Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
13
States / cities
La Jolla, California • Los Angeles, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Sep 20, 2026, 5:09 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% in Adult Participants With Actinic Keratosis

NCT05279131
View directory record Official record
Conditions
Keratosis, Actinic
Interventions
Tirbanibulin ointment 1%
Drug
Lead sponsor
Almirall, S.A.
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
7
States / cities
Hot Springs, Arkansas • Encinitas, California • Sweetwater, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2024 · Synced Sep 20, 2026, 5:09 AM EDT